Abstract:Atrial fibrillation (AF) is the most common form of arrhythmia, carrying high social costs. It is usually first seen by general practitioners or in emergency departments. Despite the availability of consensus guidelines, considerable variations exist in treatment practice, especially outside specialised cardiological settings. Cardioversion to sinus rhythm aims to: (i) restore the atrial contribution to ventricular filling/output; (ii) regularise ventricular rate; and (iii) interrupt atrial remodelling. Cardioversion always requires careful assessment of potential proarrhythmic and thromboembolic risks, and this translates into the need to personalise treatment decisions. Among the many clinical variables that affect strategy selection, time from onset is crucial. In selected patients, pharmacological cardioversion of recent-onset AF can be a safely used, feasible and effective approach, even in internal medicine and emergency departments. In most cases of recent-onset AF, pharmacological cardioversion provides an important--and probably more cost effective--alternative to electrical cardioversion, which can then be employed as a second-line therapy for nonresponders. Class IC agents (flecainide or propafenone), which can be safely used in hospitalised patients with recent-onset AF without left ventricular dysfunction, can provide rapid conversion to sinus rhythm after either intravenous administration or oral loading. Although intravenous amiodarone requires longer conversion times, it is still the standard treatment for patients with heart failure. Ibutilide also provides good conversion rates and could be used for AF patients with left ventricular dysfunction (were it not for high costs). For long-lasting AF most pharmacological treatments have only limited efficacy and electrical cardioversion remains the gold standard in this setting. However, a widely used strategy involves pretreatment with amiodarone in the weeks before planned electrical cardioversion: this provides optimal prophylaxis and can sometimes even restore sinus rhythm. Dofetilide may also be capable of restoring sinus rhythm in up to 25-30% of patients and can be used in patients with heart failure. The potential risk of proarrhythmia increases the need for careful therapeutic decision making and management of pharmacological cardioversion. The results of recent trials (AFFIRM [Atrial Fibrillation Follow-up Investigation of Rhythm Management] and RACE [Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation]) on rate versus rhythm control strategies in the long term have led to a generalised shift in interest towards rate control. Although carefully designed studies are required to better define the role of pharmacological rhythm control in specific AF settings, this alternative option remains a recommendable strategy for many patients, especially those in acute care.

Management of arrhythmia in sepsis and septic shock

Evaluation of Amiodarone Administration in Patients with New-Onset Atrial Fibrillation in Septic Shock

Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study

Echocardiography predictors of sustained sinus rhythm after cardioversion of supraventricular arrhythmia in patients with septic shock

Treating critical supraventricular and ventricular arrhythmias

Vasoactive Agents for the Treatment of Sepsis.

Short-term and long-term outcomes of cardiac arrhythmias in patients with cardiogenic shock

The outcomes of patients with septic shock treated with propafenone compared to amiodarone for supraventricular arrhythmias are related to end-systolic left atrial volume

Ivabradine in Septic Shock: A Narrative Review

Update on management of cardiac arrhythmias in acute coronary syndromes

Pharmacotherapy in Ventricular Arrhythmias

[Heart Rate Control in Patients with Sepsis and Septic Cardiomyopathy: the Role of Ivabradine].

Pharmacological cardioversion of atrial fibrillation: current management and treatment options

Pathophysiology and treatment of adults with arrhythmias in the emergency department, part 1: Atrial arrhythmias

The autonomic nervous system in septic shock and its role as a future therapeutic target: a narrative review

Central Venous-To-Arterial Carbon Dioxide Partial Pressure Difference As A Guiding Parameter For Cardiotonic Drug Administration In Patients With Early-Stage Septic Shock

Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy

Vasoactive pharmacologic therapy in cardiogenic shock: a critical review

Practical Considerations in Sepsis Resuscitation

Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium

Pharmacological cardioversion of atrial fibrillation: practical considerations